Delving into the Latest Updates on Lomerizine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Lomerazine, Lomerizine, Lomerizine hydrochloride (JAN)

+ [6]

Target

calcium channel

Action

inhibitors

Mechanism

calcium channel inhibitors(Calcium Channel inhibitors)

Therapeutic Areas

Nervous System Diseases

Active Indication

Migraine Disorders

Inactive Indication

Brain InfarctionGlaucoma

Originator Organization

Pfizer Japan, Inc.

Active Organization

Nanjing Changao Pharmaceutical Science & Technology Co. Ltd.

Pfizer Japan, Inc.MSD KK

Inactive Organization

Merck & Co., Inc.

Santen Pharmaceutical Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

Japan (12 Mar 1999),

Migraine Disorders

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC27H30F2N2O3

InChIKeyJQSAYKKFZOSZGJ-UHFFFAOYSA-N

CAS Registry101477-55-8

View All Structures (2)

OBJECTIVESCerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is one of the most common monogenic cerebral small vessel diseases. Our previous observational study suggested that lomerizine hydrochloride, a calcium channel blocker approved in Japan in 1999 for the prevention of migraine headaches, is also effective for preventing recurrent ischemic stroke in CADASIL patients. The aim of this study (LOMCAD trial) is to verify the efficacy of lomerizine hydrochloride.MATERIALS AND METHODSThis is a multicenter, prospective, single-arm trial, using a historical control for comparison. CADASIL patients with a history of two or more cerebral ischemic events within the last two years will be administered lomerizine hydrochloride (5-mg tablet twice daily) for 24 months. The primary endpoint is symptomatic cerebral ischemic events during the 24-month period. Using our historical data and Bayesian sample size calculation based on a prior predictive distribution, the planned sample size was determined as 20 subjects.CONCLUSIONWe have planned a clinical trial to verify the effectiveness of lomerizine hydrochloride as prophylaxis to prevent recurrent cerebral ischemic events in CADASIL patients.REGISTRATIONThe LOMCAD trial has been registered in the Japan Registry of Clinical Trials (jRCTs051220072, https://jrct.niph.go.jp/latest-detail/jRCTs051220072).

01 Oct 2024·Cureus

A Case of Migraine Treated Through Hybrid Consultation via In-Person and Online Telemedicine at an Occupational Health Nurse's Office.

Article

Author: Ooka, Miho ; Katsuki, Masahito ; Sato, Daiki ; Wada, Yasuhiro ; Nakata, Yuki

An occupational doctor cannot perform medical procedures, such as diagnosis and prescription. They can only give advice to the workplace. Online telemedicine facilitates workplace-doctor collaboration and may solve this problem. We present the first case of migraine treated by hybrid consultation via in-person and online telemedicine at the occupational health office. In the present case, a 36-year-old male had experienced headaches since age 15 and had been diagnosed with migraine. He was on prophylactic treatment with 10 mg of lomerizine, experiencing one monthly migraine attack, often relieved by 50 mg of sumatriptan. His Headache Impact Test-6 (HIT-6) score was 56 at the consultation. He visited the occupational health nurse's office due to a migraine attack. An occupational doctor assessed him and diagnosed a migraine attack. The patient requested triptans, but only over-the-counter acetaminophen was available, and the doctor could not prescribe medication because the doctor was just an occupational doctor, and the nurse's office was not a clinic under the Japanese Medical Act. The occupational doctor, who was also hired by the other clinic as a physician, conducted an online consultation via the clinic at the nurse's office, diagnosed a migraine attack, and prescribed 50 mg of sumatriptan. The prescription was sent to a nearby pharmacy, and the patient found relief within 15 minutes after taking the triptan. Regular online consultation at the nurse's office has been continued, and prophylactic medications were strengthened. His migraine frequency decreased once in five months, and the HIT-6 score improved to 50. Performing online telemedicine at the workplace, such as the occupational nurse's office, could overturn the conventional wisdom that occupational physicians cannot perform medical treatment at non-medical institutions and can only refer patients to other clinics based on the Japanese Medical Act. Our case suggested the importance of strategic collaboration between occupational doctors and telemedicine-enabled medical facilities in ensuring seamless healthcare delivery, particularly for busy workers.

09 Sep 2024·Angewandte Chemie International Edition

Development of Iron‐Based Single Atom Materials for General and Efficient Synthesis of Amines

Article

Author: Zbořil, Radek ; Kreyenschulte, Carsten ; Menezes, Prashanth W. ; Bartling, Stephan ; Haumann, Michael ; Beller, Matthias ; Ma, Zhuang ; Kuloor, Chakreshwara ; Jagadeesh, Rajenahally V. ; Malina, Ondrej

AbstractEarth abundant metal‐based heterogeneous catalysts with highly active and at the same time stable isolated metal sites constitute a key factor for the advancement of sustainable and cost‐effective chemical synthesis. In particular, the development of more practical, and durable iron‐based materials is of central interest for organic synthesis, especially for the preparation of chemical products related to life science applications. Here, we report the preparation of Fe‐single atom catalysts (Fe‐SACs) entrapped in N‐doped mesoporous carbon support with unprecedented potential in the preparation of different kinds of amines, which represent privileged class of organic compounds and find increasing application in daily life. The optimal Fe‐SACs allow for the reductive amination of a broad range of aldehydes and ketones with ammonia and amines to produce diverse primary, secondary, and tertiary amines including N‐methylated products as well as drugs, agrochemicals, and other biomolecules (amino acid esters and amides) utilizing green hydrogen.

100 Deals associated with Lomerizine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02633	Lomerizine Hydrochloride	N02C	DB14065

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Migraine Disorders	Japan	Pfizer Japan, Inc.	12 Mar 1999

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Brain Infarction	Phase 2	Japan	-	-
Glaucoma	Preclinical	Japan	-	24 Aug 2003

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ARVO2014	Not Applicable	Glaucoma, Open-Angle \| Glaucoma	120	Lomerizine 10 mg	hjdenhyern(zffudzqaac) = odnaqhhdgr ustlpjmcyx (szuislataj )	Positive	01 Apr 2014
				Methylcobalamin 1500 μg	hjdenhyern(zffudzqaac) = xcylggzhxi ustlpjmcyx (szuislataj )
ARVO2010	Not Applicable	-	9	Nilvadipine	ubvgltfpds(syiuihktez) = ysthpouwid rvsjilvvjc (ccketpjnbr )	-	01 Apr 2010
				Lomerizine	ubvgltfpds(syiuihktez) = njtsmblcbu rvsjilvvjc (ccketpjnbr )
ARVO2003	Not Applicable	Optic Nerve Injuries	-	Vehicle-treated group	gutiplijmp(laknzactve) = iwylstcoha ajgxoyqbrh (grmfrizhyq )	Positive	01 May 2003
				Lomerizine 10 mg/kg	gutiplijmp(laknzactve) = aydnboxomt ajgxoyqbrh (grmfrizhyq )